SPRC (SciSparc Ltd) Short-Term Debt to Capital

SciSparc Ltd (SPRC) is developing scientific alliances with clinics to create drugs that treat brain and CNS pathologies. The business relies on a refined global delivery system for psychotropic agents, which guarantees high margins. The price trend reflected below, where the indicator is 0.73, confirms steady investor confidence and the professional community's recognition of its innovative therapy methods.

This ratio determines the share of short-term liabilities within the equity structure, measuring the business's ability to service current debts without risking insolvency. By analyzing the historical short-term debt-to-equity level, an investor can see how the SciSparc Ltd. (SPRC) strategy of minimizing costs and maintaining margins under micro-cap conditions impacts financial stability, where the metric's consistency confirms a conservative approach to liquidity.